AML Treatment Regimens - 55-Year-Old Female

Step 0 - Essential Work-up Before Treatment

• Bone marrow cytogenetics, FISH, and molecular panel (FLT3-ITD/TKD, IDH1/2, NPM1, CEBPA, TP53, RUNX1)
• European LeukemiaNet (ELN) risk stratification (Favorable / Intermediate / Adverse)
• Performance status and cardiac function (echo or MUGA)
• HLA typing (self + siblings) for potential transplant planning

1. Intensive Induction (Fit Patients)

A. Standard "7+3" Regimen - First-Line for Most Fit Patients

• Cytarabine 100-200 mg/m² as continuous IV infusion x 7 days
• Daunorubicin 60-90 mg/m² IV on Days 1, 2, 3 (daunorubicin 90 mg/m² is NOT recommended in patients >65 years due to excess toxicity)
• OR Idarubicin 12 mg/m² IV on Days 1, 2, 3 (can substitute for daunorubicin; idarubicin may produce higher CR rates)
• Achieves complete remission (CR) in ~60-80% of patients
• Harrison's Principles of Internal Medicine 22E (2025), p. 1269-1273
• Washington Manual of Medical Therapeutics, p. 864

B. 7+3 + Gemtuzumab Ozogamicin (GO)

• Gemtuzumab ozogamicin (anti-CD33 ADC) added to 7+3 when daunorubicin 60 mg/m² is used
• Recommended especially for CBF-AML (Core Binding Factor: t(8;21) or inv(16)) - favorable risk group
• Also beneficial in younger CD33-positive patients with favorable-risk disease

C. 7+3 + Midostaurin (for FLT3-Mutated AML)

• Midostaurin (multikinase FLT3 inhibitor) 50 mg orally twice daily on Days 8-21 of each cycle, added to standard 7+3
• Indicated when FLT3-ITD or FLT3-TKD mutation is present
• Improves overall survival in FLT3-mutated AML (RATIFY trial)
• Continue midostaurin during consolidation cycles as well

2. Intensive Induction for Specific AML Subtypes

D. CPX-351 (Liposomal Cytarabine:Daunorubicin)

• Fixed 5:1 molar ratio of cytarabine and daunorubicin in liposomal formulation
• Dose: 100 mg/m² cytarabine + 44 mg/m² daunorubicin on Days 1, 3, and 5
• Preferred for:
  • AML with myelodysplasia-related changes (AML-MR)
  • Therapy-related AML
  • Shown to improve OS over standard 7+3 in these subtypes in patients 60-75 years
• Goldman-Cecil Medicine, p. 2568

3. Acute Promyelocytic Leukemia (APL - M3) - SEPARATE PROTOCOL

• ATRA (All-trans retinoic acid) + Arsenic trioxide (ATO) - ATRA-ATO backbone
  • Low/intermediate-risk APL: ATRA + ATO alone (no chemotherapy needed)
  • High-risk APL (WBC >10,000): ATRA + ATO + anthracycline-based chemotherapy
• Followed by maintenance with ATRA ± chemotherapy
• Cure rates >90% with modern ATRA-ATO regimens
• Harrison's Principles of Internal Medicine 22E (2025), p. 1295

4. Lower-Intensity Regimens (Unfit/Ineligible for Intensive Chemotherapy)

E. Venetoclax + Hypomethylating Agent (HMA) - Current Standard of Care

• Venetoclax (BCL-2 inhibitor) 400 mg daily (ramp-up dosing: 100 mg Day 1, 200 mg Day 2, 400 mg Day 3+)
• Combined with:
  • Azacitidine 75 mg/m² SC/IV on Days 1-7 (28-day cycle) - VIALE-A trial
  • OR Decitabine 20 mg/m² IV on Days 1-5 (28-day cycle)
• Achieves CR in ~37% vs 18% with HMA alone; improves OS
• Now also being studied in fit/younger patients
• Recent 2025 meta-analysis (PMID 40389911) found VEN+HMA is competitive with intensive chemotherapy in certain populations

F. Glasdegib + Low-Dose Cytarabine (LDAC)

• Glasdegib (Hedgehog pathway inhibitor) 100 mg PO daily
• Combined with Low-dose cytarabine (LDAC) 20 mg SC twice daily on Days 1-10 every 28 days
• Alternative for patients ineligible for intensive therapy when venetoclax combinations are not suitable

G. Low-Dose Cytarabine (LDAC) Alone

• 20 mg SC twice daily on Days 1-10 of each 28-day cycle
• Limited efficacy; largely replaced by venetoclax combinations

5. Mutation-Targeted Therapies

• Washington Manual of Medical Therapeutics, p. 864
• Ivosidenib network meta-analysis 2025 (PMID 40491347) supports ivosidenib + azacitidine for newly diagnosed IDH1-mutated AML

6. Consolidation Therapy (After Achieving CR)

• Allogeneic HCT is the preferred consolidation for intermediate/adverse-risk patients up to age ~75 years and is recommended for essentially all older patients in CR1 who are HCT-eligible
• Harrison's Principles of Internal Medicine 22E (2025), p. 1297

7. Decision Algorithm for a 55-Year-Old

55F with AML
    |
    ├── APL (PML-RARA)? --> ATRA + ATO (+ anthracycline if high-risk)
    |
    ├── Fit for intensive therapy?
    |       |
    |       ├── FLT3 mutation? --> 7+3 + Midostaurin
    |       ├── CBF-AML / favorable? --> 7+3 + Gemtuzumab Ozogamicin
    |       ├── AML-MR / therapy-related? --> CPX-351
    |       └── Other --> Standard 7+3
    |               --> If IDH1/IDH2 mutated, add ivosidenib/enasidenib
    |
    └── Unfit for intensive therapy?
            --> Venetoclax + Azacitidine or Decitabine
            --> Glasdegib + LDAC (alternative)

8. Maintenance (Post-Consolidation)

• Oral azacitidine (CC-486) 300 mg PO daily x 14 days per 28-day cycle - approved for patients in CR/CRi after intensive therapy who are not pursuing HCT (especially non-favorable cytogenetics)
• Midostaurin continuation in FLT3-mutated AML
• Gilteritinib (post-HCT maintenance in FLT3-mutated)

Key Recent Evidence (2024-2026)

• Contemporary Management of AML - JAMA Oncology 2024 (PMID 39115831) - comprehensive review of current landscape
• VEN+HMA vs induction chemotherapy meta-analysis 2025 (PMID 40389911) - VEN+HMA shows comparable outcomes in older/unfit patients
• Azacitidine + venetoclax - "How I treat" Blood 2025 (PMID 39316723) - practical guidance for AZA-VEN dosing and management

Clinical note: At age 55, this patient is typically eligible for intensive induction unless comorbidities, poor PS, or adverse features preclude it. Molecular profiling results (especially FLT3, IDH1/2, NPM1) are critical before finalizing the regimen. Given intermediate/adverse-risk disease in this age group, planning for allogeneic HCT in CR1 should begin at diagnosis.

What "Azacitidine Days 1-7 of a 28-Day Cycle" Means

The Basic Concept - A "Cycle"

|-- Day 1 --|-- Day 2 --|-- ... --|-- Day 7 --|-- Day 8 --|-- ... --|-- Day 28 --|
   DRUG        DRUG               DRUG          REST         REST       REST
                                                        ↑
                                              Next cycle starts on Day 29 = new Day 1

• The patient receives azacitidine for a set number of days
• Then rests (no drug) for the remaining days
• On Day 29, the cycle restarts as a new "Day 1"
• This continues month after month - typically for at least 6 cycles

Standard Azacitidine Schedules

• Azacitidine 75 mg/m² subcutaneously (SC) or IV on Days 1-7 of every 28-day cycle
• This is the VIALE-A protocol dose when combined with venetoclax

Why Days 1-5 Specifically?

28-Day Calendar Block:
Day 1  → Azacitidine given ✓
Day 2  → Azacitidine given ✓
Day 3  → Azacitidine given ✓
Day 4  → Azacitidine given ✓
Day 5  → Azacitidine given ✓
Day 6  → REST (no drug)
Day 7  → REST
...
Day 28 → REST
────────────────────
Day 29 = New Day 1 → Azacitidine given again ✓ (Cycle 2 begins)

• Drug days: 5 days
• Rest days: 23 days
• Cycle length: 28 days (= 4 weeks = approximately 1 month)

Why Is There a Rest Period?

1. Bone marrow recovery - azacitidine suppresses blood cell production; rest allows counts to recover
2. Mechanism of action - azacitidine works by incorporating into DNA and RNA and demethylating gene promoters; its effect persists after the drug is stopped (so you don't need to give it every day)
3. Toxicity management - continuous dosing would cause excessive nausea, cytopenias, and organ toxicity
4. Response assessment - counts and response are evaluated at the end of each cycle before the next one starts

Practical Day-to-Day View for the Patient

Key Points to Remember

• "28-day cycle" = the drug is given, then a rest period follows, all within a 28-day (monthly) block
• Days 1-5 simply means the drug is given on the first 5 days of that 28-day block
• The number after "Days" tells you which specific days the patient receives the injection
• Cycles are numbered: Cycle 1, Cycle 2, Cycle 3... continuing as long as the patient responds and tolerates
• In combination with venetoclax, azacitidine 75 mg/m² is given on Days 1-7 of the 28-day cycle (the VIALE-A standard)

In simple terms: The patient gets an injection every day for 5 days, then goes home and rests for 3 weeks. After 4 weeks total have passed, it starts again. This monthly rhythm continues for many months.

How to Assess Performance Status (PS)

Scale 1 - ECOG / WHO / Zubrod Scale (Most Common in Oncology)

The One Key Question to Ask:

"How much of your day are you able to be up and active? What can you do for yourself? Can you work?"

ECOG Performance Status Grades

How to Remember It:

• 0 = Normal life
• 1 = Light duty only, but up all day
• 2 = Can't work, but up >50% of day
• 3 = In bed >50% of day, limited self-care
• 4 = Bedridden, no self-care
• Harrison's Principles of Internal Medicine 22E (2025), p. 601

Scale 2 - Karnofsky Performance Scale (KPS)

• Campbell-Walsh Urology, Table 6.4

Step-by-Step - How to Assess in the Clinic

Ask these questions:

"On a typical day, how much time do you spend out of bed - sitting in a chair or walking around?"

• All day = Grade 0-1
• More than half = Grade 2
• Less than half = Grade 3-4

"Are you able to do your normal job or household work?"

• Yes, fully = Grade 0
• Only light work = Grade 1
• No work at all = Grade 2+

"Can you bathe yourself, dress yourself, feed yourself?"

• Yes, fully = Grade 0-2
• Only partially = Grade 3
• Cannot at all = Grade 4

"Do you need someone else to help you with daily activities?"

• No help = Grade 0-1
• Occasional help = Grade 2
• Constant help = Grade 3-4

Clinical Relevance in AML (Your Patient)

Key cutoff in oncology:

• ECOG ≥ 3 or Karnofsky ≤ 70 = poor prognosis; intensive treatment generally not offered
• This is why performance status is assessed at diagnosis before choosing a regimen

Quick Summary

Ask yourself: "What can this patient do on a typical day?"
↓
Does everything normally          → ECOG 0 (KPS 90-100)
Light activities only, works part → ECOG 1 (KPS 70-80)
Can't work, but up >50% of day   → ECOG 2 (KPS 50-60)
In bed >50% of day               → ECOG 3 (KPS 30-40)
Completely bedridden             → ECOG 4 (KPS 10-20)